Contact us for more information

HBN-1 may offer the unique potential to pharmaceutically treat or prevent neurological damage and improve survival outcomes in post-cardiac arrest resuscitation, stroke, traumatic brain injury and spinal cord injury, as well as for other potentially life-threatening conditions. The company's first target indication will be in resuscitated post-cardiac arrest patients. There are an estimated 350,000 annual cases of cardiac arrest in the United States alone each year. The American Heart Association and ILCOR have already issued guidelines recommending the use of therapeutic hypothermia for the treatment of resuscitated post-cardiac patients but the intervention is seriously underutilized due to procedural complexity, side effects, equipment needs and cost. Based on pre-clinical evidence in translational models with a high degree of predictive value in man, it is expected that Hibernaid's easy-to-administer IV formulation could produce therapeutic hypothermia more efficiently, more effectively, more safely and with better neurological and survival outcomes than any of the current methods in use today.

Current Hypothermia Methodologies

These are essentially 'forced' or mechanical methods that may include ice baths, mechanical cooling devices, cold blankets and iced saline infusions. Forced hypothermia is difficult to control, often requires sedating drugs and induced coma, results in shivering and other adverse bodily reactions to fighting cooling, can only be performed in hospital settings with highly trained personnel, and requires either expensive equipment or extensive time investments by hospitals as well as adjunctive protocols to address unwanted effects of the procedure. HBN-1 offers a practical, safe method for rapid and safe cooling after brain injuries, is simple to administer, and doesn't require sedation, intubation and ventilator support or the induction of paralysis.